IL291791B2 - Methods for treating sleep timing disorders - Google Patents

Methods for treating sleep timing disorders

Info

Publication number
IL291791B2
IL291791B2 IL291791A IL29179122A IL291791B2 IL 291791 B2 IL291791 B2 IL 291791B2 IL 291791 A IL291791 A IL 291791A IL 29179122 A IL29179122 A IL 29179122A IL 291791 B2 IL291791 B2 IL 291791B2
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
use according
Prior art date
Application number
IL291791A
Other languages
English (en)
Hebrew (he)
Other versions
IL291791B1 (en
IL291791A (en
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL291791A publication Critical patent/IL291791A/en
Publication of IL291791B1 publication Critical patent/IL291791B1/en
Publication of IL291791B2 publication Critical patent/IL291791B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL291791A 2016-05-12 2017-05-11 Methods for treating sleep timing disorders IL291791B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662335611P 2016-05-12 2016-05-12
US201662335599P 2016-05-12 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US201662414606P 2016-10-28 2016-10-28
US201662414599P 2016-10-28 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (3)

Publication Number Publication Date
IL291791A IL291791A (en) 2022-06-01
IL291791B1 IL291791B1 (en) 2025-05-01
IL291791B2 true IL291791B2 (en) 2025-09-01

Family

ID=58745465

Family Applications (2)

Application Number Title Priority Date Filing Date
IL291791A IL291791B2 (en) 2016-05-12 2017-05-11 Methods for treating sleep timing disorders
IL262803A IL262803B (en) 2016-05-12 2018-11-06 Methods of treating circadian rhythm sleep disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL262803A IL262803B (en) 2016-05-12 2018-11-06 Methods of treating circadian rhythm sleep disorders

Country Status (16)

Country Link
US (2) US11096941B2 (https=)
EP (2) EP3454859B1 (https=)
JP (2) JP6888026B2 (https=)
KR (2) KR20230043227A (https=)
CN (1) CN109640998A (https=)
AU (3) AU2017264871B2 (https=)
CA (1) CA3022068A1 (https=)
ES (1) ES2904625T3 (https=)
IL (2) IL291791B2 (https=)
MX (1) MX379318B (https=)
MY (1) MY199382A (https=)
RU (1) RU2763493C2 (https=)
SG (1) SG11201809527UA (https=)
TW (1) TWI795359B (https=)
WO (1) WO2017197160A1 (https=)
ZA (1) ZA201807903B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3022068A1 (en) * 2016-05-12 2017-11-16 Eisai R&D Management Co., Ltd. Methods of treating circadian rhythm sleep disorders
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
BR112021026291A2 (pt) * 2019-06-26 2022-03-03 Eisai R&D Man Co Ltd Lemborexant para tratar problemas de sono
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
US12534448B2 (en) * 2019-12-11 2026-01-27 Tapi Czech Industries S.R.O Solid state form of lemborexant
US20230103250A1 (en) * 2020-01-16 2023-03-30 Eisai R&D Management Co., Ltd. Drug substance of lemborexant and medicinal composition comprising same
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
US20250064802A1 (en) * 2021-07-26 2025-02-27 Eisai R&D Management Co., Ltd. Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
TW202425995A (zh) 2022-09-23 2024-07-01 日商衛材R&D企管股份有限公司 減少與神經退化疾病相關的神經退化的方法
WO2025033432A1 (ja) 2023-08-08 2025-02-13 株式会社明治 概日リズムの調整

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556753C (en) 2004-02-20 2014-11-25 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
WO2012039371A1 (ja) 2010-09-22 2012-03-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 シクロプロパン化合物
ES2672732T3 (es) * 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
CA3022068A1 (en) * 2016-05-12 2017-11-16 Eisai R&D Management Co., Ltd. Methods of treating circadian rhythm sleep disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOSS, CHRISTOPH, ET AL.:, RECENT TRENDS IN OREXIN RESEARCH—2010 TO 2015., 15 May 2015 (2015-05-15) *
MUSIEK, ERIK S ET AL., SLEEP, CIRCADIAN RHYTHMS, AND THE PATHOGENESIS OF ALZHEIMER DISEASE, 13 March 2015 (2015-03-13) *
YOSHIDA, YU, ET AL.:, DISCOVERY OF (1 R, 2 S)-2-{[(2, 4-DIMETHYLPYRIMIDIN-5-YL) OXY] METHYL}-2-(3-FLUOROPHENYL)-N-(5-FLUOROPYRIDIN-2-YL) CYCLOPROPANECARBOXAMIDE (E2006): A POTENT AND EFFICACIOUS ORAL OREXIN RECEPTOR ANTAGONIST, 11 June 2015 (2015-06-11) *

Also Published As

Publication number Publication date
MX2018013663A (es) 2019-07-18
NZ748555A (en) 2025-06-27
US20200179382A1 (en) 2020-06-11
BR112018073037A2 (pt) 2019-02-26
ES2904625T3 (es) 2022-04-05
WO2017197160A1 (en) 2017-11-16
AU2017264871A1 (en) 2018-11-15
IL291791B1 (en) 2025-05-01
SG11201809527UA (en) 2018-11-29
MY199382A (en) 2023-10-25
MX379318B (es) 2025-03-10
AU2017264871B2 (en) 2023-03-16
EP3454859B1 (en) 2021-12-01
RU2018143809A3 (https=) 2020-09-17
KR20190013820A (ko) 2019-02-11
RU2763493C2 (ru) 2021-12-29
JP6888026B2 (ja) 2021-06-16
CA3022068A1 (en) 2017-11-16
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
JP2021120410A (ja) 2021-08-19
AU2023203418A1 (en) 2023-06-29
AU2025205336A1 (en) 2025-07-31
JP2019518732A (ja) 2019-07-04
ZA201807903B (en) 2021-04-28
IL262803B (en) 2022-05-01
TWI795359B (zh) 2023-03-11
US20210353625A1 (en) 2021-11-18
IL262803A (en) 2018-12-31
EP3454859A1 (en) 2019-03-20
EP4056180A1 (en) 2022-09-14
US11096941B2 (en) 2021-08-24
RU2018143809A (ru) 2020-06-15
JP7150096B2 (ja) 2022-10-07
IL291791A (en) 2022-06-01
CN109640998A (zh) 2019-04-16
KR102511855B1 (ko) 2023-03-20

Similar Documents

Publication Publication Date Title
IL291791B2 (en) Methods for treating sleep timing disorders
JP2019518732A5 (https=)
Ladenbauer et al. Brain stimulation during an afternoon nap boosts slow oscillatory activity and memory consolidation in older adults
Nesbitt et al. Cluster headache
Ang et al. Absent sleep EEG spindle activity in GluA1 (Gria1) knockout mice: relevance to neuropsychiatric disorders
JP2020528075A5 (https=)
RU2680247C2 (ru) Средство, усиливающее эффект реабилитации после нервного повреждения, которое содержит производное простого алкилового эфира или его соль
JP2016526974A5 (https=)
Bennett et al. Therapeutic hypothermia for status epilepticus: a report, historical perspective, and review
Carano et al. Glycopyrrolate and theophylline for the treatment of severe pallid breath-holding spells
WO2023108170A3 (en) Systems, devices, and methods for enhancing the neuroprotective effects of non-invasive gamma stimulation with pharmacological agents
ATE482711T1 (de) Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropika
Bhat et al. Increasing off-time improves sleep-disordered breathing induced by vagal nerve stimulation
PH12022552763A1 (en) Medical use of daridorexant
NZ748555B2 (en) Methods of treating circadian rhythm sleep disorders
Roth et al. Effects of medial thalamotomy and pallido-thalamic tractotomy on sleep and waking EEG in pain and Parkinsonian patients
MX2020012912A (es) Método de tratamiento con el agonista inverso del receptor de histamina-3.
FI3909568T3 (fi) Profylaktinen tai terapeuttinen lääke neurodegeneratiivisiin tauteihin
Khachatryan et al. Sleep-onset central apneas as triggers of severe nocturnal seizures
Langenbruch et al. P138. Acute onset and reversibility of triphasic waves in the EEG correlating with hypercapnia
Pedrera-Mazarro et al. Nocturnal panic attacks
Brock et al. Severe Sleep Disruption in PTSD: Trauma-Associated Sleep Disorder
Liguori et al. Unexpected total recovery in a patient with post-anoxic complete alpha coma predicted by recording of cortical SEPs
Oh et al. Central Sleep Apnea without Cheyne-Stokes Breathing Following an Acute Cerebral Infarction
Okura et al. Obstructive sleep apnea syndrome aggravated propriospinal myoclonus at sleep onset